Skip to Content

Rasuvo Approval History

FDA Approved: Yes (First approved July 11, 2014)
Brand name: Rasuvo
Generic name: methotrexate
Dosage form: Injection
Previous Name: MPI-2505
Company: Medac Pharma, Inc.
Treatment for: Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Psoriasis

Rasuvo (methotrexate) is a subcutaneous, ready-to-use autopen formulation of methotrexate for the treatment of rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis.

Development History and FDA Approval Process for Rasuvo

DateArticle
Jul 14, 2014Approval FDA Approves Rasuvo (methotrexate) Injection
Jan 27, 2014Medac Pharma, Inc. Secures FDA Acceptance of a New Drug Application (NDA) for Methotrexate-Containing Autopen

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide